Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation

International Journal of Obesity

Volumn 27, Issue , 2003, Pages S17-S21

  Moller, D E ^a   Berger, J P ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Fibrate; Inflammation; Insulin resistance; Peroxisome proliferator activated receptor (PPAR); Thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; FIBRIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CONFERENCE PAPER; DIABETES MELLITUS; DISEASE MARKER; DYSLIPIDEMIA; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID LIVER LEVEL; LIPID METABOLISM; METABOLIC REGULATION; MOLECULAR MECHANICS; MUSCLE LEVEL; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; HUMANS; INFLAMMATION; INSULIN RESISTANCE; LIGANDS; OBESITY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

ANIMALIA;

EID: 0346880507     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0802494     Document Type: Article

References (31)

1. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000; 43: 527–550.
2. Barroso I, Gurnell M, Crowley VEF, Agostini M, Schwabe JW, Soos MA, Maslen G, Williams TDM, Lewis H, Schafer AJ, Chatterjee VKK, O’Rahilly S. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus, and hypertension. Nature 1999; 402: 880–883.
3. Berger J, Moller DE. The mechanism of action of PPARs. Ann Rev Med 2002; 53: 409–435.
4. Moller D, Greene D. PPARγ agonists for diabetes. In: Scolnick E (ed) Drug discovery and design. Academic Press: New York; 2001. pp 181–212.
5. Chao L, Marcus-Samuels B, Mason MM, Moitra J, Vinson C, Arioglu E, Gavrilova O, Reitman M. Adipose tissue is required for the antidiabetic, but not the hypolipidemic, effect of thiazolidinediones. J Clin Invest 2000; 106: 1221–1228.
6. Zierath JR, Ryder JW, Doebber T, Woods J, Wu M, Ventre J, Li Z, McCrary C, Berger J, Zhang B, Moller DE. Role of skeletal muscle in thiazolidinedione insulin sensitizer action. Endocrinology 1998; 139: 5034–5041.
7. Berger J, Biswas C, Hayes N, Ventre J, Wu M, Doebber TW. An antidiabetic thiazolidinedione potentiates insulin stimulation of glycogen synthase in rat adipose tissue. Endocrinology 1996; 137: 1984–1990.
8. Berger J, Tanen M, Elbrecht A, Hermanowski-Vosatka A, Moller DE, Wright SD, Thieringer R. Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta-hydroxysteroid dehydrogenase type 1 expression and activity. J Biol Chem 2001; 276: 12629–12635.
9. Masuzaki H, Paterson J, Shinyama H, Morton N, Mullins J, Seckl J, Flier J. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294: 2166–2170.
10. Guan H-P, Li Y, Jensen M, Newgard C, Steppan C, Lazar M. A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med 2002; 8: 1122–1128.
11. Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert J, Winegar D, Willson T, Fruchart J, Staels B. Peroxisome proliferator-activated receptor a activators improve insulin sensitivity and reduce adiposity. J Biol Chem 2000; 275: 16638–16642.
12. Ye J, Doyle P, Iglesias M, Watson D, Cooney G, Kraegen E. Peroxisome proliferator-activated receptor-a activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats. Diabetes 2001; 50: 411–417.
13. Oliver WR, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 2001; 98: 5306–5311.
14. Rubins HB, Robins SJ. Conclusions from the VA-HIT study. Am J Cardiol 2000; 86: 543–544.
15. Pasceri V, Wu HD, Willerson JT, Yeh ETH. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferatoractivated receptor-g activators. Circulation 2000; 101: 235–238.
16. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 1996; 384: 39–43.
17. Delerive P, Fruchart J-C, Staels B. Peroxisome proliferatoractivated receptors in inflammation control. J Endocrinol 2001; 169: 453–459.
18. Moore K, Fitzgerald M, Freeman M. Peroxisome proliferatoractivated receptors in macrophage biology: friend or foe? Curr Opin Lipidol 2001; 12: 519–527.
19. Thieringer R, Fenyk-Melody JE, Le Grand CB, Shelton BA, Detmers PA, Somers EP, Carbin L, Moller DE, Wright SD, Berger J. Activation of peroxisome proliferator-activated receptor g does not inhibit IL-6 or TNF-α responses of macrophages to LPS in vitro or in vivo. J Immunol 2000; 164: 1046–1054.
20. Wang N, Verna L, Chen N-G, Chen J, Li H, Forman B, Stemerman M. Constitutive activation of peroxisome proliferator-activated receptor-g suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. J Biol Chem 2002; 277: 34176–34181.
21. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87–91.
22. Lin Y, Rajala M, Berger J, Moller D, Barzilai N, Scherer P. Hyperglycemia-induced production of acute phase reactants. J Biol Chem 2001; 276: 42077–42083.
23. Moller D. Potential role of TNF-α in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2000; 11: 212–217.
24. Miles PDG, Romeo OM, Higo K, Cohen A, Rafaat K, Olefsky JM. TNF-alpha induced insulin resistance in vivo and its prevention by troglitazone. Diabetes 1997; 46: 1678–1683.
25. Berg AH, Combatsiaris TC, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7: 947–953.
26. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595–1599.
27. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H, Hotta K, Muraguchi M, Ohmoto Y, Yamashita S, Funahashi T. Adipocytederived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103: 1057–1063.
28. Combs T, Wagner J, Berger J, Doebber T, Zhang B, Tanen M, O’Rahilly S, Savage J, Berg A, Larson P, Gottesdiener K, Gertz B, Scherer P, Moller D. Induction of Acrp30 levels by PPARγ agonists: a potential mechanism of insulin sensitization. Endocrinology 2002; 143: 998–1007.
29. Aljada A, Garg R, Ghanim H, Mohanty P, Hamouda W, Assian E, Dandona P. Nuclear factor kB suppressive and inhibitor kB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? J Clin Endocrinol Metab 2001; 86: 3250–3256.
30. Ebeling P, Teppo A, Koistinen H, Viikari J, Ronnemaa T, Nissen M, Bergkulla S, Salmela P, Saltevo J, Koivisto V. Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with type II diabetes. Diabetologia 1999; 42: 1433–1438.
31. Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Dhindsa S, Dandona P. Evidence for a potent anti-inflammatory effect of rosiglitazone in obese patients (abstract). Proceedings of the Annual Meeting; Endocrine Society 2002; 408: P2–P376.